Opinion Editorial: Huge lawsuit awards are hidden tax on Pennsylvania residents
Curt Schroder, Executive Director of PCCJR | The Morning Call | November 29, 2019
Out-of-staters have long flocked to the Philadelphia courts for their lawsuits. An example is the recent $8 billion punitive damage award against Johnson & Johnson, which will not only make “litigation tourism” even more attractive to plaintiffs’ lawyers, but could also end up costing every Pennsylvania household.
The Philadelphia jury found the company liable over its marketing of the anti-psychotic drug Risperdal, siding with a Maryland man who argued that the company downplayed the risk of the drug causing breast growth in boys.
According to one legal publication, the $8 billion award against Johnson & Johnson is possibly the largest verdict in Pennsylvania history. In addition to threatening the livelihoods of Johnson & Johnson employees who make prescription drugs and medical devices, this nuclear verdict puts an exclamation point on unchecked legal abuses that must be addressed. Read more at The Morning Call.
PA Supreme Court reinstates thousands of Risperdal cases
Nicholas Malfitano | Penn Record |November 26, 2019
According to a pair of majority rulings from the Supreme Court of Pennsylvania, a factual analysis must be undertaken in each individual case involving Johnson & Johnson anti-psychotic drug Risperdal, before a jury can decide when the statute of limitations begins to toll for bringing a claim.